Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 01-05-2017 | Review

Gut microbiota and colorectal cancer

Authors: R. Gao, Z. Gao, L. Huang, H. Qin

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2017

Abstract

The gut microbiota is considered as a forgotten organ in human health and disease. It maintains gut homeostasis by various complex mechanisms. However, disruption of the gut microbiota has been confirmed to be related to gastrointestinal diseases such as colorectal cancer, as well as remote organs in many studies. Colorectal cancer is a multi-factorial and multi-stage involved disorder. The role for microorganisms that initiate and facilitate the process of colorectal cancer has become clear. The candidate pathogens have been identified by culture and next sequencing technology. Persuasive models have also been proposed to illustrate the complicated and dynamic time and spatial change in the carcinogenesis. Related key molecules have also been investigated to demonstrate the pathways crucial for the development of colorectal cancer. In addition, risk factors that contribute to the tumorigenesis can also be modulated to decrease the susceptibility for certain population. In addition, the results of basic studies have also translated to clinical application, which displayed a critical value for the diagnosis and therapy of colorectal cancer. In this review, we not only emphasize the exploration of the mechanisms, but also potential clinical practice implication in this microbiota era.

Zheng R, Zeng H, Zhang S, Chen T, Chen W (2016) National estimates of cancer prevalence in China, 2011. Cancer Lett 370(1):33–38. doi:10.1016/j.canlet.2015.10.003 PubMedCrossRef

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. doi:10.3322/caac.21338 PubMedCrossRef

Peters U, Bien S, Zubair N (2015) Genetic architecture of colorectal cancer. Gut 64(10):1623–1636. doi:10.1136/gutjnl-2013-306705 PubMedPubMedCentralCrossRef

Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97(22):1679–1687. doi:10.1093/jnci/dji375 PubMedCrossRef

Shao T, Yang YX (2005) Cholecystectomy and the risk of colorectal cancer. Am J Gastroenterol 100(8):1813–1820. doi:10.1111/j.1572-0241.2005.41610.x PubMedCrossRef

Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, Overvad K, Olsen A, Tjonneland A, Clavel F, Boutron-Ruault MC, Kesse E, Boeing H, Bergmann MM, Nieters A, Linseisen J, Trichopoulou A, Trichopoulos D, Tountas Y, Berrino F, Palli D, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Engeset D, Lund E, Skeie G, Ardanaz E, Gonzalez C, Navarro C, Quiros JR, Sanchez MJ, Berglund G, Mattisson I, Hallmans G, Palmqvist R, Day NE, Khaw KT, Key TJ, San Joaquin M, Hemon B, Saracci R, Kaaks R, Riboli E (2005) Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 97(12):906–916. doi:10.1093/jnci/dji164 PubMedPubMedCentralCrossRef

Larsson SC, Wolk A (2006) Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer J Int Cancer 119(11):2657–2664. doi:10.1002/ijc.22170 CrossRef

Magalhaes B, Peleteiro B, Lunet N (2012) Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev: Off J Eur Cancer Prev Org 21(1):15–23. doi:10.1097/CEJ.0b013e3283472241 CrossRef

Bardou M, Barkun AN, Martel M (2013) Obesity and colorectal cancer. Gut 62(6):933–947. doi:10.1136/gutjnl-2013-304701 PubMedCrossRef

10.

Kamada N, Chen GY, Inohara N, Nunez G (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14(7):685–690. doi:10.1038/ni.2608 PubMedPubMedCentralCrossRef

11.

Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C, Relman DA, Kasper DL (2012) Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149(7):1578–1593. doi:10.1016/j.cell.2012.04.037 PubMedPubMedCentralCrossRef

12.

Brenchley JM, Douek DC (2012) Microbial translocation across the GI tract. Annu Rev Immunol 30:149–173. doi:10.1146/annurev-immunol-020711-075001 PubMedPubMedCentralCrossRef

13.

Zeng MY, Cisalpino D, Varadarajan S, Hellman J, Warren HS, Cascalho M, Inohara N, Nunez G (2016) Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens. Immunity 44(3):647–658. doi:10.1016/j.immuni.2016.02.006 PubMedPubMedCentralCrossRef

14.

Wang L, Fouts DE, Starkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B (2016) Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe 19(2):227–239. doi:10.1016/j.chom.2016.01.003 PubMedPubMedCentralCrossRef

15.

Spano S, Gao X, Hannemann S, Lara-Tejero M, Galan JE (2016) A bacterial pathogen targets a host Rab-family GTPase defense pathway with a GAP. Cell Host Microbe 19(2):216–226. doi:10.1016/j.chom.2016.01.004 PubMedPubMedCentralCrossRef

16.

Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O’Sullivan O, Fitzgerald GF, Deane J, O’Connor M, Harnedy N, O’Connor K, O’Mahony D, van Sinderen D, Wallace M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross RP, O’Toole PW (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature 488(7410):178–184. doi:10.1038/nature11319 PubMed

17.

Spor A, Koren O, Ley R (2011) Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9(4):279–290. doi:10.1038/nrmicro2540 PubMedCrossRef

18.

Clarke SF, Murphy EF, O’Sullivan O, Lucey AJ, Humphreys M, Hogan A, Hayes P, O’Reilly M, Jeffery IB, Wood-Martin R, Kerins DM, Quigley E, Ross RP, O’Toole PW, Molloy MG, Falvey E, Shanahan F, Cotter PD (2014) Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63(12):1913–1920. doi:10.1136/gutjnl-2013-306541 PubMedCrossRef

19.

Marlicz W, Loniewski I (2015) The effect of exercise and diet on gut microbial diversity. Gut 64(3):519–520. doi:10.1136/gutjnl-2014-307909 PubMedCrossRef

20.

Salonen A, de Vos WM (2014) Impact of diet on human intestinal microbiota and health. Annu Rev Food Sci Technol 5:239–262. doi:10.1146/annurev-food-030212-182554 PubMedCrossRef

21.

Gagniere J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, Bringer MA, Pezet D, Bonnet M (2016) Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 22(2):501–518. doi:10.3748/wjg.v22.i2.501 PubMedPubMedCentralCrossRef

22.

Gupta A, Madani R, Mukhtar H (2010) Streptococcus bovis endocarditis, a silent sign for colonic tumour. Color Dis: Off J Assoc Coloproctol Great Britain Ireland 12(3):164–171. doi:10.1111/j.1463-1318.2009.01814.x CrossRef

23.

Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M (2012) Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22(2):292–298. doi:10.1101/gr.126573.111 PubMedPubMedCentralCrossRef

24.

Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM (2015) Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One 10(3):e0119462. doi:10.1371/journal.pone.0119462 PubMedPubMedCentralCrossRef

25.

Gao Z, Guo B, Gao R, Zhu Q, Qin H (2015) Microbiota disbiosis is associated with colorectal cancer. Front Microbiol 6:20. doi:10.3389/fmicb.2015.00020 PubMedPubMedCentral

26.

Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R (2013) High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 8(2):e56964. doi:10.1371/journal.pone.0056964 PubMedPubMedCentralCrossRef

27.

Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22(2):299–306. doi:10.1101/gr.126516.111 PubMedPubMedCentralCrossRef

28.

Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L (2012) Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 6(2):320–329. doi:10.1038/ismej.2011.109 PubMedCrossRef

29.

Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L (2013) Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 105(24):1907–1911. doi:10.1093/jnci/djt300 PubMedPubMedCentralCrossRef

30.

Chen W, Liu F, Ling Z, Tong X, Xiang C (2012) Human Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal Cancer. PLoS One 7(6):e39743. doi:10.1371/journal.pone.0039743.t001 PubMedPubMedCentralCrossRef

31.

Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338(6103):120–123. doi:10.1126/science.1224820 PubMedPubMedCentralCrossRef

32.

Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Dechelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A (2014) Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 20(4):859–867. doi:10.1158/1078-0432.CCR-13-1343 PubMedCrossRef

33.

Kohoutova D, Smajs D, Moravkova P, Cyrany J, Moravkova M, Forstlova M, Cihak M, Rejchrt S, Bures J (2014) Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect Dis 14:733. doi:10.1186/s12879-014-0733-7 PubMedPubMedCentralCrossRef

34.

Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, Su L, Li X, Li X, Li J, Xiao L, Huber-Schonauer U, Niederseer D, Xu X, Al-Aama JY, Yang H, Wang J, Kristiansen K, Arumugam M, Tilg H, Datz C, Wang J (2015) Gut microbiome development along the colorectal adenoma–carcinoma sequence. Nat Commun 6:6528. doi:10.1038/ncomms7528 PubMedCrossRef

35.

Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J, Sung JJ (2015) Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 6:8727. doi:10.1038/ncomms9727 PubMedPubMedCentralCrossRef

36.

Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, Igarashi H, Takahashi T, Tachibana M, Takahashi H, Yoshii S, Takenouchi T, Hasegawa T, Okita K, Hirata K, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y (2015) Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 137(6):1258–1268. doi:10.1002/ijc.29488 PubMedCrossRef

37.

Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, O’Riordain M, Shanahan F, O’Toole PW (2016) Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. doi:10.1136/gutjnl-2015-309595 PubMed

38.

Zhu Q, Jin Z, Wu W, Gao R, Guo B, Gao Z, Yang Y, Qin H (2014) Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One 9(6), e90849. doi:10.1371/journal.pone.0090849 PubMedPubMedCentralCrossRef

39.

Li Y, Kundu P, Seow SW, de Matos CT, Aronsson L, Chin KC, Karre K, Pettersson S, Greicius G (2012) Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 33(6):1231–1238. doi:10.1093/carcin/bgs137 PubMedCrossRef

40.

Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD (2013) The gut microbiome modulates colon tumorigenesis. MBio 4(6):e00692-00613. doi:10.1128/mBio.00692-13 CrossRef

41.

Baxter NT, Zackular JP, Chen GY, Schloss PD (2014) Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. Microbiome 2:20. doi:10.1186/2049-2618-2-20 PubMedPubMedCentralCrossRef

42.

Gay NJ, Symmons MF, Gangloff M, Bryant CE (2014) Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 14(8):546–558. doi:10.1038/nri3713 PubMedCrossRef

43.

Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A (1999) Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285(5428):736–739PubMedCrossRef

44.

Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ (1999) Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 274(25):17406–17409PubMedCrossRef

45.

Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A (1999) The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401(6755):811–815. doi:10.1038/44605 PubMedCrossRef

46.

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413(6857):732–738. doi:10.1038/35099560 PubMedCrossRef

47.

Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274(16):10689–10692PubMedCrossRef

48.

Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633):640–643. doi:10.1126/science.1087262 PubMedCrossRef

49.

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663):1526–1529. doi:10.1126/science.1093620 PubMedCrossRef

50.

Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101(15):5598–5603. doi:10.1073/pnas.0400937101 PubMedPubMedCentralCrossRef

51.

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408(6813):740–745. doi:10.1038/35047123 PubMedCrossRef

52.

Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. J Immunol 168(9):4531–4537. doi:10.4049/jimmunol.168.9.4531 PubMedCrossRef

53.

Barton GM, Medzhitov R (2003) Toll-like receptor signaling pathways. Science 300(5625):1524–1525. doi:10.1126/science.1085536 PubMedCrossRef

54.

Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4(7):499–511. doi:10.1038/nri1391 PubMedCrossRef

55.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311(5768):1770–1773. doi:10.1126/science.1123933 PubMedCrossRef

56.

Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ (2000) Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 165(2):903–914PubMedCrossRef

57.

Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7(12):1250–1257. doi:10.1038/ni1412 PubMedCrossRef

58.

Kanneganti TD, Lamkanfi M, Nunez G (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27(4):549–559. doi:10.1016/j.immuni.2007.10.002 PubMedCrossRef

59.

Perez-Lopez A, Rosales-Reyes R, Alpuche-Aranda CM, Ortiz-Navarrete V (2013) Salmonella downregulates Nod-like receptor family CARD domain containing protein 4 expression to promote its survival in B cells by preventing inflammasome activation and cell death. J Immunol 190(3):1201–1209. doi:10.4049/jimmunol.1200415 PubMedCrossRef

60.

Biswas A, Petnicki-Ocwieja T, Kobayashi KS (2012) Nod2: a key regulator linking microbiota to intestinal mucosal immunity. J Mol Med (Berl) 90(1):15–24. doi:10.1007/s00109-011-0802-y CrossRef

61.

Natividad JM, Petit V, Huang X, de Palma G, Jury J, Sanz Y, Philpott D, Garcia Rodenas CL, McCoy KD, Verdu EF (2012) Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. Inflamm Bowel Dis 18(8):1434–1446. doi:10.1002/ibd.22848 PubMedCrossRef

62.

Petnicki-Ocwieja T, Hrncir T, Liu YJ, Biswas A, Hudcovic T, Tlaskalova-Hogenova H, Kobayashi KS (2009) Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A 106(37):15813–15818. doi:10.1073/pnas.0907722106 PubMedPubMedCentralCrossRef

63.

Robertson SJ, Zhou JY, Geddes K, Rubino SJ, Cho JH, Girardin SE, Philpott DJ (2013) Nod1 and Nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis. Gut Microbes 4(3):222–231. doi:10.4161/gmic.24373 PubMedPubMedCentralCrossRef

64.

Wen H, Miao EA, Ting JP (2013) Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 39(3):432–441. doi:10.1016/j.immuni.2013.08.037 PubMedCrossRef

65.

Eisenbarth SC, Williams A, Colegio OR, Meng H, Strowig T, Rongvaux A, Henao-Mejia J, Thaiss CA, Joly S, Gonzalez DG, Xu L, Zenewicz LA, Haberman AM, Elinav E, Kleinstein SH, Sutterwala FS, Flavell RA (2012) NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 484(7395):510–513. doi:10.1038/nature11012 PubMedPubMedCentralCrossRef

66.

Zaki MH, Vogel P, Malireddi RK, Body-Malapel M, Anand PK, Bertin J, Green DR, Lamkanfi M, Kanneganti TD (2011) The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 20(5):649–660. doi:10.1016/j.ccr.2011.10.022 PubMedPubMedCentralCrossRef

67.

Tjalsma H, Boleij A, Marchesi JR, Dutilh BE (2012) A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 10(8):575–582. doi:10.1038/nrmicro2819 PubMedCrossRef

68.

Hajishengallis G, Darveau RP, Curtis MA (2012) The keystone-pathogen hypothesis. Nat Rev Microbiol 10(10):717–725. doi:10.1038/nrmicro2873 PubMedPubMedCentralCrossRef

69.

Sears CL, Garrett WS (2014) Microbes, microbiota, and colon cancer. Cell Host Microbe 15(3):317–328. doi:10.1016/j.chom.2014.02.007 PubMedPubMedCentralCrossRef

70.

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14(2):195–206. doi:10.1016/j.chom.2013.07.012 PubMedPubMedCentralCrossRef

71.

Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14(2):207–215. doi:10.1016/j.chom.2013.07.007 PubMedPubMedCentralCrossRef

72.

Dharmani P, Strauss J, Ambrose C, Allen-Vercoe E, Chadee K (2011) Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun 79(7):2597–2607. doi:10.1128/IAI.05118-11 PubMedPubMedCentralCrossRef

73.

Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S, Shussman N, Almogy G, Cuapio A, Hofer E, Mevorach D, Tabib A, Ortenberg R, Markel G, Miklic K, Jonjic S, Brennan CA, Garrett WS, Bachrach G, Mandelboim O (2015) Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42(2):344–355. doi:10.1016/j.immuni.2015.01.010 PubMedPubMedCentralCrossRef

74.

Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, Lynch T, Allen-Vercoe E (2011) Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 17(9):1971–1978. doi:10.1002/ibd.21606 PubMedCrossRef

75.

Greenblum S, Carr R, Borenstein E (2015) Extensive strain-level copy-number variation across human gut microbiome species. Cell 160(4):583–594. doi:10.1016/j.cell.2014.12.038 PubMedPubMedCentralCrossRef

76.

Sears CL, Islam S, Saha A, Arjumand M, Alam NH, Faruque AS, Salam MA, Shin J, Hecht D, Weintraub A, Sack RB, Qadri F (2008) Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Clin Infect Dis 47(6):797–803. doi:10.1086/591130 PubMedPubMedCentralCrossRef

77.

Sears CL (2001) The toxins of Bacteroides fragilis. Toxicon 39(11):1737–1746PubMedCrossRef

78.

Rhee KJ, Wu S, Wu X, Huso DL, Karim B, Franco AA, Rabizadeh S, Golub JE, Mathews LE, Shin J, Sartor RB, Golenbock D, Hamad AR, Gan CM, Housseau F, Sears CL (2009) Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun 77(4):1708–1718. doi:10.1128/IAI.00814-08 PubMedPubMedCentralCrossRef

79.

Housseau F, Sears CL (2014) Enterotoxigenic bacteroides fragilis (ETBF)-mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis. Cell Cycle 9(1):3–5. doi:10.4161/cc.9.1.10352 CrossRef

80.

Hwang S, Gwon SY, Kim MS, Lee S, Rhee KJ (2013) Bacteroides fragilis toxin Induces IL-8 secretion in HT29/C1 cells through disruption of E-cadherin junctions. Immune Netw 13(5):213–217. doi:10.4110/in.2013.13.5.213 PubMedPubMedCentralCrossRef

81.

Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15(9):1016–1022. doi:10.1038/nm.2015 PubMedPubMedCentralCrossRef

82.

Wu S, Morin PJ, Maouyo D, Sears CL (2003) Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 124(2):392–400. doi:10.1053/gast.2003.50047 PubMedCrossRef

83.

Sears CL, Geis AL, Housseau F (2014) Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest 124(10):4166–4172. doi:10.1172/JCI72334 PubMedPubMedCentralCrossRef

84.

Magdy A, Elhadidy M, Abd Ellatif ME, El Nakeeb A, Abdallah E, Thabet W, Youssef M, Khafagy W, Morshed M, Farid M (2015) Enteropathogenic Escherichia coli (EPEC): Does it have a role in colorectal tumourigenesis? A prospective cohort study. Int J Surg 18:169–173. doi:10.1016/j.ijsu.2015.04.077 PubMedCrossRef

85.

Martin HM, Campbell BJ, Hart CA, El Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM (2004) Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterol 127(1):80–93 doi: 10.1053/j.gastro.2004.03.054 CrossRef

86.

Raisch J, Buc E, Bonnet M, Sauvanet P, Vazeille E, de Vallee A, Dechelotte P, Darcha C, Pezet D, Bonnet R, Bringer MA, Darfeuille-Michaud A (2014) Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation. World J Gastroenterol 20(21):6560–6572. doi:10.3748/wjg.v20.i21.6560 PubMedPubMedCentralCrossRef

87.

Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrede JP (2010) Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A 107(25):11537–11542. doi:10.1073/pnas.1001261107 PubMedPubMedCentralCrossRef

88.

Maddocks OD, Scanlon KM, Donnenberg MS (2013) An Escherichia coli effector protein promotes host mutation via depletion of DNA mismatch repair proteins. MBio 4(3):e00152-00113. doi:10.1128/mBio.00152-13 CrossRef

89.

Vizcaino MI, Crawford JM (2015) The colibactin warhead crosslinks DNA. Nat Chem 7(5):411–417. doi:10.1038/nchem.2221 PubMedPubMedCentralCrossRef

90.

Bronowski C, Smith SL, Yokota K, Corkill JE, Martin HM, Campbell BJ, Rhodes JM, Hart CA, Winstanley C (2008) A subset of mucosa-associated Escherichia coli isolates from patients with colon cancer, but not Crohn’s disease, share pathogenicity islands with urinary pathogenic E. coli. Microbiology 154(Pt 2):571–583. doi:10.1099/mic.0.2007/013086-0 PubMedCrossRef

91.

Choi HJ, Kim J, Do KH, Park SH, Moon Y (2013) Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: an in vitro implication of infection-linked tumor dissemination. Oncogene 32(41):4960–4969. doi:10.1038/onc.2012.508 PubMedCrossRef

92.

Raisch J, Rolhion N, Dubois A, Darfeuille-Michaud A, Bringer MA (2015) Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression. Lab Investig 95(3):296–307. doi:10.1038/labinvest.2014.161 PubMedCrossRef

93.

He X, Mishchuk DO, Shah J, Weimer BC, Slupsky CM (2013) Cross-talk between E. coli strains and a human colorectal adenocarcinoma-derived cell line. Scientific Rep 3:3416. doi:10.1038/srep03416

94.

Song X, Gao H, Lin Y, Yao Y, Zhu S, Wang J, Liu Y, Yao X, Meng G, Shen N, Shi Y, Iwakura Y, Qian Y (2014) Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity 40(1):140–152. doi:10.1016/j.immuni.2013.11.018 PubMedCrossRef

95.

Centuori SM, Martinez JD (2014) Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. Dig Dis Sci 59(10):2367–2380. doi:10.1007/s10620-014-3190-7 PubMedPubMedCentralCrossRef

96.

Sharon G, Garg N, Debelius J, Knight R, Dorrestein PC, Mazmanian SK (2014) Specialized metabolites from the microbiome in health and disease. Cell Metab 20(5):719–730. doi:10.1016/j.cmet.2014.10.016 PubMedPubMedCentralCrossRef

97.

Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, Wilson KE, Glover LE, Kominsky DJ, Magnuson A, Weir TL, Ehrentraut SF, Pickel C, Kuhn KA, Lanis JM, Nguyen V, Taylor CT, Colgan SP (2015) Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17(5):662–671. doi:10.1016/j.chom.2015.03.005 PubMedPubMedCentralCrossRef

98.

Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63(8):1275–1283. doi:10.1136/gutjnl-2013-304833 PubMedCrossRef

99.

Rossi O, van Berkel LA, Chain F, Tanweer Khan M, Taverne N, Sokol H, Duncan SH, Flint HJ, Harmsen HJ, Langella P, Samsom JN, Wells JM (2016) Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Scientific Rep 6:18507. doi:10.1038/srep18507 CrossRef

100.

Quevrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermudez-Humaran LG, Pigneur B, Lequin O, Kharrat P, Thomas G, Rainteau D, Aubry C, Breyner N, Afonso C, Lavielle S, Grill JP, Chassaing G, Chatel JM, Trugnan G, Xavier R, Langella P, Sokol H, Seksik P (2016) Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 65(3):415–425. doi:10.1136/gutjnl-2014-307649 PubMedCrossRef

101.

Hornef MW, Pabst O (2016) Real friends: Faecalibacterium prausnitzii supports mucosal immune homeostasis. Gut 65(3):365–367. doi:10.1136/gutjnl-2015-310027 PubMedCrossRef

102.

Zackular JP, Rogers MA, Ruffin MT, Schloss PD (2014) The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res 7(11):1112–1121. doi:10.1158/1940-6207.CAPR-14-0129 CrossRef

103.

Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Bohm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, von Knebel Doeberitz M, Sobhani I, Bork P (2014) Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 10:766. doi:10.15252/msb.20145645 PubMedPubMedCentralCrossRef

104.

Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, Wang X, Xu X, Chen N, Wu WK, Al-Aama J, Nielsen HJ, Kiilerich P, Jensen BA, Yau TO, Lan Z, Jia H, Li J, Xiao L, Lam TY, Ng SC, Cheng AS, Wong VW, Chan FK, Xu X, Yang H, Madsen L, Datz C, Tilg H, Wang J, Brunner N, Kristiansen K, Arumugam M, Sung JJ, Wang J (2015) Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. doi:10.1136/gutjnl-2015-309800

105.

Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA (2015) Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 148(1):77.e2–87.e2. doi:10.1053/j.gastro.2014.09.038 CrossRef

106.

Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M, Jenab M, Prehn JH, Hughes DJ (2014) Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 33(8):1381–1390. doi:10.1007/s10096-014-2081-3 PubMedCrossRef

107.

Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Garraway LA, Freeman GJ, Dranoff G, Garrett WS, Huttenhower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S (2015) Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. doi:10.1136/gutjnl-2015-310101 PubMedCentral

108.

Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S (2015) Fusobacterium nucleatum and T Cells in colorectal carcinoma. JAMA Oncol 1(5):653–661. doi:10.1001/jamaoncol.2015.1377 PubMedPubMedCentralCrossRef

109.

Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estecio MR, Issa JP (2014) Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 74(5):1311–1318. doi:10.1158/0008-5472.CAN-13-1865 PubMedPubMedCentralCrossRef

110.

Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Berard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–1084. doi:10.1126/science.aad1329 PubMedPubMedCentralCrossRef

111.

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084–1089. doi:10.1126/science.aac4255 PubMedPubMedCentralCrossRef

112.

Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334(6052):105–108. doi:10.1126/science.1208344 PubMedPubMedCentralCrossRef

113.

Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, Gougis S, Rizkalla S, Batto JM, Renault P, consortium ANRM, Dore J, Zucker JD, Clement K, Ehrlich SD (2013) Dietary intervention impact on gut microbial gene richness. Nature 500(7464):585–588. doi:10.1038/nature12480 PubMedCrossRef

114.

Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64(1):93–100. doi:10.1136/gutjnl-2014-307264 PubMedCrossRef

115.

David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505(7484):559–563. doi:10.1038/nature12820 PubMedCrossRef

116.

Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Backhed F (2015) Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab 22(4):658–668. doi:10.1016/j.cmet.2015.07.026 PubMedPubMedCentralCrossRef

117.

Chung WS, Walker AW, Louis P, Parkhill J, Vermeiren J, Bosscher D, Duncan SH, Flint HJ (2016) Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol 14(1):3. doi:10.1186/s12915-015-0224-3 PubMedPubMedCentralCrossRef

118.

Turroni F, Milani C, Duranti S, Mancabelli L, Mangifesta M, Viappiani A, Lugli GA, Ferrario C, Gioiosa L, Ferrarini A, Li J, Palanza P, Delledonne M, van Sinderen D, Ventura M (2016) Deciphering bifidobacterial-mediated metabolic interactions and their impact on gut microbiota by a multi-omics approach. ISME J 10(7):1656–1668. doi:10.1038/ismej.2015.236 PubMedCrossRef

119.

Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, van-Hylckama Vlieg JE, Strissel K, Zhao L, Obin M, Shen J (2015) Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J 9(1):1–15. doi:10.1038/ismej.2014.99 PubMedCrossRef

120.

Gao Z, Guo B, Gao R, Zhu Q, Wu W, Qin H (2015) Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol Med Rep 12(4):6119–6127. doi:10.3892/mmr.2015.4124 PubMed

121.

Bindels LB, Delzenne NM, Cani PD, Walter J (2015) Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 12(5):303–310. doi:10.1038/nrgastro.2015.47 PubMedCrossRef

122.

van Zanten GC, Krych L, Roytio H, Forssten S, Lahtinen SJ, Abu Al-Soud W, Sorensen S, Svensson B, Jespersen L, Jakobsen M (2014) Synbiotic Lactobacillus acidophilus NCFM and cellobiose does not affect human gut bacterial diversity but increases abundance of lactobacilli, bifidobacteria and branched-chain fatty acids: a randomized, double-blinded cross-over trial. FEMS Microbiol Ecol 90(1):225–236. doi:10.1111/1574-6941.12397 PubMedCrossRef

123.

Cougnoux A, Delmas J, Gibold L, Fais T, Romagnoli C, Robin F, Cuevas-Ramos G, Oswald E, Darfeuille-Michaud A, Prati F, Dalmasso G, Bonnet R (2015) Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut 65(2):278–285. doi:10.1136/gutjnl-2014-307241 PubMedCrossRef

124.

Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY, An HF, Weng YR, Yu J, Li M, Qin WX, Ma X, Shen N, Hong J, Fang JY (2015) Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget 6(31):32013–32026. doi:10.18632/oncotarget.5166 PubMedPubMedCentral

125.

Jalanka J, Salonen A, Salojarvi J, Ritari J, Immonen O, Marciani L, Gowland P, Hoad C, Garsed K, Lam C, Palva A, Spiller RC, de Vos WM (2015) Effects of bowel cleansing on the intestinal microbiota. Gut 64(10):1562–1568. doi:10.1136/gutjnl-2014-307240 PubMedCrossRef

126.

Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A (2016) The gut microbiota and host health: a new clinical frontier. Gut 65(2):330–339. doi:10.1136/gutjnl-2015-309990 PubMedCrossRef

Title: Gut microbiota and colorectal cancer
Authors: R. Gao
Z. Gao
L. Huang
H. Qin
Publication date: 01-05-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-016-2881-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gut microbiota and colorectal cancer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Selective persistence of Propionibacterium species FMA5 following sealing of infected dentinal matrix

Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children

Evaluation of the novel artus C. difficile QS-RGQ, VanR QS-RGQ and MRSA/SA QS-RGQ assays for the laboratory diagnosis of Clostridium difficile infection (CDI), and for vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) screening

Author’s reply

Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page